Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or …
The effects of exposure to solar radiation on human health
This assessment by the Environmental Effects Assessment Panel (EEAP) of the Montreal
Protocol under the United Nations Environment Programme (UNEP) evaluates the effects of …
Protocol under the United Nations Environment Programme (UNEP) evaluates the effects of …
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
AM Goodman, S Kato, L Bazhenova… - Molecular cancer …, 2017 - aacrjournals.org
Immunotherapy induces durable responses in a subset of patients with cancer. High tumor
mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors …
mutational burden (TMB) may be a response biomarker for PD-1/PD-L1 blockade in tumors …
Update from the 5th edition of the world health organization classification of head and neck tumors: overview of the 2022 WHO classification of head and neck …
O Mete, BM Wenig - Head and neck pathology, 2022 - Springer
This review article provides a brief overview of the new WHO classification by adopting a
question–answer model to highlight the spectrum of head and neck neuroendocrine …
question–answer model to highlight the spectrum of head and neck neuroendocrine …
Genomic correlates of response to immune checkpoint blockade
TE Keenan, KP Burke, EM Van Allen - Nature medicine, 2019 - nature.com
Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …
term benefit to the majority of patients with cancer. Understanding genomic correlates of …
Targeting neoantigens to augment antitumour immunity
The past decade of cancer research has been marked by a growing appreciation of the role
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …
of immunity in cancer. Mutations in the tumour genome can cause tumours to express …
Merkel cell carcinoma
Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with
neuroendocrine features. MCC pathogenesis is associated with either the presence of …
neuroendocrine features. MCC pathogenesis is associated with either the presence of …
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …
Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy
PURPOSE Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …
Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway inhibitors for …